Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mark Rametta"'
Publikováno v:
Neurology and Therapy. 11:373-384
It is important to achieve good persistence and adherence to disease-modifying therapies (DMTs) to achieve the best outcomes in chronic diseases such as multiple sclerosis (MS). The BETACONNECT device is an electronic auto-injector for the DMT interf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c86ffd86633b9494eb33e50a61442ad
https://doi.org/10.1007/s40120-022-00323-1
https://doi.org/10.1007/s40120-022-00323-1
Autor:
Sandy Yeo, Ann-Kathrin Frenz, Simone Heeg, Oisin Butler, Katsiaryna Holl, Eva-Maria Wicklein, Mark Rametta
Publikováno v:
Drugs-Real World Outcomes
Background Both interferon beta-1b (IFN-β-1b) and interferon beta-1a (IFN-β-1a) are immunomodulators that require regular subcutaneous self-administration by patients with multiple sclerosis (MS). However, no electronic autoinjector is available fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f7bfb0bef87afbc7dd76b540b43f20
http://europepmc.org/articles/PMC8324614
http://europepmc.org/articles/PMC8324614
Publikováno v:
Neurology and Therapy. 7:59-85
Numerous observational studies have suggested that there is a correlation between the level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a literature search of large, prospective, observation studies, epidemiologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b20915c63d3cb02d01333a6016f55cb9
https://doi.org/10.1007/s40120-017-0086-4
https://doi.org/10.1007/s40120-017-0086-4
Autor:
Oisin Butler, Ann-Kathrin Frenz, Katsiaryna Holl, Mark Rametta, S. Werner, S. Yeo, Eva-Maria Wicklein
Publikováno v:
Value in Health. 23:S258-S259
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72f8dae004cdb5af82679a0b0a9c2853
https://doi.org/10.1016/j.jval.2020.04.898
https://doi.org/10.1016/j.jval.2020.04.898
Publikováno v:
Neurology and Therapy
Introduction Multiple sclerosis (MS) typically requires life-long management with disease-modifying therapies (DMTs). Many DMTs require regular self-injection, and can be associated with injection site reactions, pain, and needle/injection phobia—b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f93440fd4c15c6149a57d45ed5a388ea
http://europepmc.org/articles/PMC4685867
http://europepmc.org/articles/PMC4685867
Publikováno v:
Multiple Sclerosis and Related Disorders. 3:294-302
Clinical trials have generated a wealth of data on the safety profile of interferon β-1b for patients with multiple sclerosis (MS). In general, interferon β-1b has not been associated with serious or life-threatening side effects during long-term t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e497e2717707102ed25fda54152853f
https://doi.org/10.1016/j.msard.2013.11.005
https://doi.org/10.1016/j.msard.2013.11.005
Autor:
Joseph A. Barone, Mark Rametta, Jessica R. Giaquinto, Juan C. Nadal, Valentina Pampulevski, Michael Toscani
Publikováno v:
Therapeutic Innovation & Regulatory Science. :216847901882108
Patients and health care professionals receive information about pharmaceutical companies through various sources, including but not limited to print media, social media, and electronic media. The objective of this research was to benchmark the senti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7097fe823614d0626e6cce9764d8e4f8
https://doi.org/10.1177/2168479018821084
https://doi.org/10.1177/2168479018821084
Autor:
Mark Rametta, Ashton MediCom, Salfords, Surrey, Uk, Lloyd Kasper, Mirla Avila, Raymond Ashton, Nicole Sconzo, Tanuja Chitnis
Publikováno v:
US Neurology. 15:82
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2c573b77bba82e4d6e8c395213c1d79
https://doi.org/10.17925/usn.2019.15.2.82
https://doi.org/10.17925/usn.2019.15.2.82
Autor:
George C. Ebers, Anthony T. Reder, T.M. DeSimone, K. Beckmann, Gary Cutter, Douglas S. Goodin, Marcelo Kremenchutzky, Dawn Langdon, Volker Knappertz, Mark Rametta, Joel Oger
Objective: To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal randomized clinical trial (RCT), retaining (in the analysis) the original randomized tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9dc68745dc9202a4cf8f984db2d1901
https://doi.org/10.1212/wnl.0b013e3182535cf6
https://doi.org/10.1212/wnl.0b013e3182535cf6
Publikováno v:
Neurology and Therapy
Introduction Patients with multiple sclerosis (MS) generally undergo long-term treatment with disease-modifying therapies (DMTs). In the US, patients taking glatiramer acetate, interferon beta-1a, or interferon beta-1b, typically use a mechanical aut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d8c6b79ad736fe9343e1c7c07a3de9
https://pubmed.ncbi.nlm.nih.gov/27277705
https://pubmed.ncbi.nlm.nih.gov/27277705